Fig. 2

Summary of risk difference results of the indirect comparison of CAB + RPV LA Q8W relative to SoC A by outcome, B virologic suppression (HIV RNA < 50 copies/mL as per FDA snapshot algorithm) results stratified by baseline third active drug class, and C lack of virologic suppression (HIV ≥ 50 copies/mL as per FDA Snapshot Algorithm) results stratified by baseline third active drug class. ^aFavors CAB + RPV Q8W. ^bMean difference. ^cValues could not be calculated for RR and OR as value for SoC in ATLAS/FLAIR was 0. AE adverse event, ATLAS/FLAIR antiretroviral therapy as long-acting suppression/first long-acting injectable regimen, CAB cabotegravir, CI confidence interval, HIV-1 human immunodeficiency virus type 1, INSTI integrase strand inhibitor, ISR injection-site reaction, LA Long-acting, NNRTI non-nucleoside reverse transcriptase inhibitor, OR Odds ratio, PI protease inhibitor, Q8W every 8 weeks, RNA ribonucleic acid, RPV rilpivirine, RR Relative risk, SoC standard of care